Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Tissue-Agnostic Cancer Therapy Approvals. Local targets link to admitted publications; unresolved targets remain external evidence.
FDA approvals of oncology drugs for tissue-agnostic indications
10.1007/s11523-023-00982-6 · 2023 · External reference
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
10.1158/1078-0432.ccr-23-0090 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
2022 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2022 · External reference
Precision Oncology for BRAF Mutant Cancers with BRAF and MEK inhibitors: From Melanoma to Tissue-agnostic therapy
10.1016/j.esmoop.2023.100788 · 2023 · External reference
The role of BRAF V600 mutation in melanoma
10.1186/1479-5876-10-85 · 2012 · External reference
Mutations of the BRAF gene in human cancer
10.1038/nature00766 · 2002 · External reference
Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: Systematic review and meta-analysis
10.1111/jop.13278 · 2022 · External reference
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
10.3389/fmolb.2020.00113 · 2020 · External reference
Comparison of diagnostic methods for the detection of a BRAF mutation in papillary thyroid cancer
2019 · External reference
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors
10.1200/edbk_404770 · 2023 · External reference
Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H
10.1200/jco.20.00762 · 2020 · External reference
Dabrafenib plus trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results
2020 · External reference
Unresolved reference
External reference
Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma
2022 · External reference
Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial
10.1038/s41591-022-02181-8 · 2023 · External reference
Unresolved reference
2022 · External reference
The development of a potent, KDRNEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers
10.1016/s0959-8049(16)33028-3 · 2016 · External reference
Selective RET kinase inhibition for patients with RET-altered cancers
10.1093/annonc/mdy137 · 2018 · External reference
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
10.1038/nrclinonc.2017.175 · 2018 · External reference
RET tyrosine kinase signaling in development and cancer
10.1016/j.cytogfr.2005.05.010 · 2005 · External reference
The RET proto-oncogene in human cancers
10.1038/sj.onc.1203857 · 2000 · External reference
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
10.1093/hmg/2.7.851 · 1993 · External reference
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
10.1038/367375a0 · 1994 · External reference
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
10.1038/363458a0 · 1993 · External reference
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
10.1016/j.annonc.2020.11.021 · 2021 · External reference
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
10.1038/nm.2673 · 2012 · External reference
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer
10.1200/jco.2012.44.1477 · 2012 · External reference
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies
10.1186/s12885-015-1146-8 · 2015 · External reference
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
10.1038/bjc.2014.36 · 2014 · External reference
Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma
10.1016/j.lungcan.2013.07.009 · 2013 · External reference
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics
10.1016/j.jtho.2016.05.021 · 2016 · External reference
Thyroid carcinoma: molecular pathways and therapeutic targets
10.1038/modpathol.2008.10 · 2008 · External reference
Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma
10.1097/jto.0000000000000135 · 2014 · External reference
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer
10.1016/j.jtho.2017.10.021 · 2018 · External reference
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
10.1177/17588359231177015 · 2023 · External reference
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
10.1016/s1470-2045(22)00541-1 · 2022 · External reference
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
10.1056/nejmoa2005653 · 2020 · External reference
Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II Trial
2022 · External reference
Efficacy of selpercatinib in RET-altered thyroid cancers
10.1056/nejmoa2005651 · 2020 · External reference
Strategies for Mitigating Adverse Events Related to Selective RET Inhibitors in Patients with RET-altered Cancers
10.1016/j.xcrm.2023.101332 · 2023 · External reference
Targeting TRK family proteins in cancer
10.1016/j.pharmthera.2017.02.006 · 2017 · External reference
NTRK fusion-positive cancers and TRK inhibitor therapy
10.1038/s41571-018-0113-0 · 2018 · External reference
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
10.1038/ng0298-184 · 1998 · External reference
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
10.1136/esmoopen-2015-000023 · 2016 · External reference
NTRK fusions in solid tumours: what every pathologist needs to know
10.1016/j.pathol.2023.05.002 · 2023 · External reference
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
10.1016/s1470-2045(19)30691-6 · 2020 · External reference
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
10.1016/s1470-2045(19)30856-3 · 2020 · External reference
Larotrectinib: First Global Approval
10.1007/s40265-018-1044-x · 2019 · External reference
Pembrolizumab (Keytruda)
10.1080/21645515.2016.1199310 · 2016 · External reference
Tumor Mutation Burden and Cancer Treatment
10.1001/jamaoncol.2020.6371 · 2021 · External reference
Microsatellite instability: a review of what the oncologist should know
10.1186/s12935-019-1091-8 · 2020 · External reference
Landscape of Microsatellite Instability Across 39 Cancer Types
2017 · External reference
A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
10.1038/s41598-022-23319-1 · 2022 · External reference
Tumor mutation burden: from comprehensive mutational screening to the clinic
10.1186/s12935-019-0929-4 · 2019 · External reference
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >/=10: a decision centered on empowering patients and their physicians
10.1016/j.annonc.2020.07.002 · 2020 · External reference
Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer
10.1038/s41598-021-91974-x · 2021 · External reference
Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
2021 · External reference
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
10.1200/jco.21.01440 · 2021 · External reference
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
2023 · External reference
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.001 · 2022 · External reference
Dostarlimab: A Review
10.3390/biom12081031 · 2022 · External reference
Unresolved reference
External reference
Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation
10.1200/jco.23.00434 · 2023 · External reference
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
10.1016/s1470-2045(23)00275-9 · 2023 · External reference
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
10.1200/jco.2023.41.17_suppl.lba3000 · 2023 · External reference
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
10.1200/jco.2022.40.16_suppl.105 · 2022 · External reference
First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation
10.1200/jco.2022.40.16_suppl.3003 · 2022 · External reference
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
10.1038/s41698-023-00449-x · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)
10.1182/blood-2021-148103 · 2021 · External reference
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
10.1089/thy.2019.0133 · 2019 · External reference
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?
10.1080/14737140.2022.2069097 · 2022 · External reference
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
10.1200/jco.22.01351 · 2023 · External reference
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series
10.1089/thy.2022.0506 · 2023 · External reference
Neoadjuvant selpercatinib for advanced medullary thyroid cancer
10.1002/hed.26527 · 2021 · External reference
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
10.1002/cncr.31701 · 2018 · External reference
